427 results about "Geometric isomer" patented technology

The present invention relates to pyrimidine and triazine compounds represented as a general formula I, geometric isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, wherein substituents R1, R2, R3 and X have the meanings defined in the description. The invention further relates to uses of the compounds represented as the general formula I in preparing medicine for treating and / or preventing cancer and other hyperplasia diseases.

The invention discloses hetero-aromatic compounds and applications thereof in pharmacy. Specifically, the invention provides hetero-aromatic compounds, and steric isomers, geometric isomers, tautomers, racemic bodies, nitrogen oxides, hydrates, solvates, metabolism products, and pharmaceutically acceptable salts or prodrug thereof. The compounds mentioned above can be used to treat autoimmune diseases or proliferative diseases. The invention also discloses a pharmaceutical composition comprising the compounds mentioned above, and an application of the compounds or the pharmaceutical composition in the preparation of drugs for treating autoimmune diseases or proliferative diseases.

An electronic device includes a semiconductor layer in contact with a number of electrodes, wherein the semiconductive layer includes a compound wherein either or both of the following geometric isomers of the compound are present: wherein: n is 1, 2 or 3 for the polycyclic moiety; and R1 and R2 are independently selected from the group consisting of a hydrocarbon ring and a heterocyclic group, wherein R1 and R2 are the same or different hydrocarbon ring, the same or different heterocyclic group, or one of R1 and R2 is the hydrocarbon ring and the other the heterocyclic group.

The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected from the group comprising or consisting of H and C1–C6-alkyl, for the prevention and / or treatment of preterm labor, premature birth or dysmenorrhea

Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

A rigid thermoplastic polyurethane made by reacting a diisocyanate with a diol, wherein the diisocyanate includes a mixture of positional and geometric isomers of bis(isocyanatomethyl) cyclohexane.

This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.

The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compounds^ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. (Formula I)

A shortening system, such as a spray shortening system; for instance, a shortening system containing unhydrogenated or non-hydrogenated vegetable oil, such as a highly unsaturated, non-hydrogenated or unhydrogenated vegetable oil, e.g., soybean oil or canola oil and a minimum or minor amount (e.g., by weight about 3-10%, advantageously about 3-7%, more advantageously about 3-6% or about 3-5% or less than about 6% or less than about 8%) of conserved trans monoglyceride and / or diglyceride, advantageously a monoglyceride or a mono- and diglyceride that is mostly monoglyceride, based on a highly unsaturated ‘oil, such as a highly unsaturated vegetable oil, e.g., canola or soybean oil,’ which has been selectively and partially hydrogenated so as to result in conservation of the geometric isomer of the C18:1 ester, namely the C18:1t or elaidic ester, as well as to methods for making and using such a shortening system, products from the use of such a shortening system, and the monoglyceride and / or diglyceride constituent of the shortening system, and methods for making and uses thereof.

An electronic device includes a semiconductor layer in contact with a number of electrodes, wherein the semiconductive layer includes a compound wherein either or both of the following geometric isomers of the compound are present: wherein:n is 1, 2 or 3 for the polycyclic moiety; andR1 and R2 are independently selected from the group consisting of a hydrocarbon ring and a heterocyclic group, wherein R1 and R2 are the same or different hydrocarbon ring, the same or different heterocyclic group, or one of R1 and R2 is the hydrocarbon ring and the other the heterocyclic group.

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

Disclosed are compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).